Nxera Pharma Co Ltd (SOLTF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Now, it is time. From now, we would like to start Nexera Pharma's FY2025 for your financial results briefing. Thank you very much for joining despite your very busy schedule. I will be serving as the MC today, CFO Nomura. Today, we have Mr. Chris Cargill, CEO, COO, President of Nexera Pharma Japan, Toshihiro Maeda, CSO, President of Nexera Pharma UK, Dr. Patrick Forsh attending the meeting. We have simultaneous interpretation as usual. Please click the globe icon and select the language, Japanese or English, and you will be able to hear the interpreter's voice. If not, you will be able to hear the original voice of the speakers. In the first half, I will be presenting and there will be q a session in the second half of the session we have the materials shared on the screen we are also uploading on the website if you would like to have the materials from investors our library presentation and please access to the materials In the latter half of the session in Q&A, institutional investors, analysts, and media people, you will be able to ask questions by raising hand. The others will be able to submit questions from Q&A button. You will be able to submit questions at any time, and we will like to respond to questions as long as the time permits. Without further ado, we would like to move on to the presentation. I will talk about the financial result. After that, Chris will talk about the operating highlights. Mr. Maeda will talk about the Japan commercial business update. Patrick will provide update on UK R&D progress. And lastly, Chris will talk about FY2026 objectives and beyond. Now, please turn to page 5 of the materials. This is page 5 of the materials. Here, summary of FY2025 four-year financial results along with the past trend by revenue segment is indicated. Th...